Have a feature idea you'd love to see implemented?
Let us know!
KALA Kala Pharmaceuticals Inc
Price (delayed)
$6.55
Market cap
$30.2M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$12.28
Enterprise value
$18.03M
Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery
Highlights
The EPS rose by 46% year-on-year and by 11% since the previous quarter
Kala Pharmaceuticals's net income has increased by 16% YoY
KALA's quick ratio has plunged by 62% YoY and by 27% from the previous quarter
Kala Pharmaceuticals's equity has decreased by 50% QoQ and by 39% YoY
Key stats
What are the main financial stats of KALA
Market
Valuations
Earnings
Shares outstanding
4.61M
Market cap
$30.2M
Enterprise value
$18.03M
Price to earnings (P/E)
N/A
Price to book (P/B)
4.4
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$33.1M
EBITDA
-$32.52M
Free cash flow
-$32.63M
Per share
Balance sheet
Liquidity
EPS
-$12.28
Free cash flow per share
-$7.05
Book value per share
$1.49
Revenue per share
$0
TBVPS
$11.69
Total assets
$54.08M
Total liabilities
$47.22M
Debt
$37.04M
Equity
$6.86M
Working capital
$27.41M
Debt to equity
5.4
Current ratio
2.15
Quick ratio
2.06
Net debt/EBITDA
0.37
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-69.4%
Return on equity
-448.6%
Return on invested capital
-125.7%
Return on capital employed
-109.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KALA stock price
How has the Kala Pharmaceuticals stock price performed over time
Intraday
1.87%
1 week
-3.11%
1 month
25%
1 year
8.62%
YTD
-6.43%
QTD
14.91%
Financial performance
How have Kala Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$40.32M
Net income
-$38.96M
Gross margin
N/A
Net margin
N/A
Kala Pharmaceuticals's net income has increased by 16% YoY
KALA's operating income is down by 2.9% YoY but it is up by 2.3% QoQ
Growth
What is Kala Pharmaceuticals's growth rate over time
Valuation
What is Kala Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.4
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS rose by 46% year-on-year and by 11% since the previous quarter
The price to book (P/B) is 57% higher than the last 4 quarters average of 2.8 and 38% higher than the 5-year quarterly average of 3.2
Kala Pharmaceuticals's equity has decreased by 50% QoQ and by 39% YoY
Efficiency
How efficient is Kala Pharmaceuticals business performance
The return on equity has dropped by 72% year-on-year and by 13% since the previous quarter
The ROIC fell by 13% QoQ and by 6% YoY
The company's return on assets fell by 7% YoY and by 3.9% QoQ
Dividends
What is KALA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KALA.
Financial health
How did Kala Pharmaceuticals financials performed over time
The total assets is 15% more than the total liabilities
KALA's current ratio has shrunk by 62% YoY and by 30% QoQ
KALA's quick ratio has plunged by 62% YoY and by 27% from the previous quarter
The debt to equity has soared by 101% from the previous quarter and by 68% YoY
Kala Pharmaceuticals's equity has decreased by 50% QoQ and by 39% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.